Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 5/20 | 0.39 |
| ▸ | ACHE | P22303 | 5/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24211443 | 0.88 | POLB (0.48) | TSHRRARBMEN1KMT2A | |
| SCHEMBL24211322 | 0.85 | KDM4E (0.40) | TTR | |
| SCHEMBL14200146 | 0.79 | SMN1; SMN2 (0.56) | BCHEACHESMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL29038755 | 0.78 | TSHR (0.41) | TSHRBCHEACHEMEN1RAB9A | |
| SCHEMBL14228281 | 0.78 | TSHR (0.51) | TSHRMEN1KMT2ASMN1; SMN2TDP1 | |
| SCHEMBL9202287 | 0.78 | ALDH1A1 (0.51) | TSHRMAPTHTT | |
| SCHEMBL24211278 | 0.76 | MYC (0.65) | MEN1KMT2A | |
| SCHEMBL15660519 | 0.74 | MYC (0.54) | TSHRMEN1KMT2A | |
| SCHEMBL24211325 | 0.73 | TTR (0.51) | TSHRRAB9ATTRLMNAHTT | |
| SCHEMBL22035 | 0.71 | TSHR (0.50) | TSHRTAS1R3TAS1R1MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017454-A1 | OLIGO-BENZAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017454-A1 | OLIGO-BENZAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT | OGFR, OTC, HDAC6 | TSHR 3324/4885BCHE 1913/4885ACHE 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.